Howard Coke
Nephrology · Greenville, NCNPI 1811349095
Payments from drug & device makers
Across 92 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$445
- Otsuka America Pharmaceutical, Inc.$171
- AstraZeneca$167
- Bayer$155
- Vifor Pharma, Inc.$134
- Aurinia Pharma U.S., Inc.$108
- plus $662 from 16 others
What the payments were for
- Food & beverage$1,836100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $445 |
| Otsuka America Pharmaceutical, Inc. | 8 | $171 |
| AstraZeneca(2 entities) | 8 | $167 |
| Bayer | 9 | $155 |
| Vifor Pharma, Inc. | 6 | $134 |
| Aurinia Pharma U.S., Inc. | 5 | $108 |
| OPKO Pharmaceuticals, LLC | 6 | $97 |
| Amgen(2 entities) | 4 | $95 |
| Calliditas Therapeutics US Inc. | 5 | $92 |
| Pharmacosmos Therapeutics Inc. | 2 | $50 |
| Daiichi Sankyo Inc. | 2 | $48 |
| ANI Pharmaceuticals, Inc. | 2 | $35 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $34 |
| GSK | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Veloxis Pharmaceuticals, Inc. | 1 | $27 |
| B. Braun Medical Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 2 | $5 |
How this compares
$1,841 in reported general payments places this provider in the 50th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 11 | $220,054 |
| VelphoroSucroferric Oxyhydroxide | 12 | $40,543 |
| KerendiaFinerenone | 47 | $38,490 |
| RayaldeeCalcifediol | 22 | $28,868 |
| JardianceEmpagliflozin | 31 | $23,281 |
| FarxigaDapagliflozin Propanediol | 31 | $21,913 |
| Sevelamer Carbonate | 27 | $11,846 |
| Cinacalcet Hcl | 20 | $5,730 |
| Torsemide | 115 | $2,252 |
| Clonidine | 11 | $1,868 |
| Amlodipine Besylate | 137 | $1,313 |
| Losartan Potassium | 83 | $1,000 |
| Midodrine Hcl | 11 | $899 |
| Lisinopril | 64 | $734 |
| Nifedipine ErNifedipine | 22 | $730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $171 | $220,05411 claims |
| Fresenius USA Marketing, Inc.Velphoro | $34 | $40,54312 claims |
| BayerKerendia | $155 | $38,49047 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $97 | $28,86822 claims |
| Boehringer IngelheimJardiance | $34 | $23,28131 claims |
| AstraZenecaFarxiga | $167 | $21,91331 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $35 | $21314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Greenville
- Nauman ShahidGreenville$2M
- Cynthia ChristianoGreenville$494K
- Reginald ObiGreenville$328K
- Paul BolinGreenville$227K
- William KendrickGreenville$125K
- Daniel EdmonstonDurham$9.9M
- Gregory GreenwoodWinston-Salem$4.1M
- Barry FreedmanWinston Salem$3.5M
- Manuel MonteroNew Bern$2.5M
- Rekha JohnKinston$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.